IQV Stock Recent News

Explore IQVIA's (IQV) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

IQVIA Holdings Inc.'s Q1 results highlighted strong profitability, robust TAS growth, and a healthy backlog, reaffirming its leadership in healthcare data and analytics. Despite sector headwinds, I remained bullish on IQVIA and expected Q2 to meet or beat estimates, viewing analyst forecasts as a conservative floor. The company did not disappoint. Key risks include delayed clinical trials, shrinking CSMS segment, regulatory challenges, and high debt, but these do not shake my conviction.

IQVIA Holdings Inc. (NYSE:IQV ) Q2 2025 Earnings Conference Call July 22, 2025 9:00 AM ET Company Participants Ari Bousbib - CEO & Chairman Kerri Joseph - Corporate Participant SVP of Investment Relation & Treasury - Corporate Participant Ronald E. Bruehlman - Executive VP & CFO Conference Call Participants Ann Kathleen Hynes - Mizuho Securities USA LLC, Research Division Christine Rains - William Blair & Company L.L.C.

IQV tops second-quarter 2025 estimates, with earnings up 6.4% and revenue rising 5.5%. It cuts the 2025 EBITDA guidance.

Major U.S. equities indexes were mixed at midday Tuesday as investors digested the latest corporate earnings. The Dow was higher, but the S&P 500 and Nasdaq lost ground.

IQVIA Holdings (IQV) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $2.64 per share a year ago.

Contract research firm IQVIA Holdings posted second-quarter profit and revenue above Wall Street expectations on Tuesday, as demand rose for its healthcare data and analytics services, sending shares up around 8% in premarket trading.

Get a deeper insight into the potential performance of IQVIA (IQV) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

IQV is set to report Q2 results on July 22, with both earnings and revenues expected to rise on strong demand across segments.

I rate IQVIA as a hold due to long-term competitive threats, particularly from one player, and concerns about capital allocation and high debt. IQVIA's business model is solid, but declining gross margins, low ROIC, and slow innovation raise concerns about its ability to sustain long-term value. The competitor's more innovative, integrated ecosystem and better capital discipline position it to capture market share from IQVIA, especially among small biotechs and large pharma.